<DOC>
	<DOCNO>NCT01902160</DOCNO>
	<brief_summary>This phase I trial study side effect best dose temsirolimus give together brentuximab vedotin treat patient Hodgkin lymphoma return respond treatment . Temsirolimus may stop growth cancer cell block enzymes need cell growth . Biological therapy , brentuximab vedotin , may stimulate immune system different way stop cancer cell grow . Giving temsirolimus brentuximab vedotin may work well treat patient Hodgkin lymphoma .</brief_summary>
	<brief_title>Temsirolimus Brentuximab Vedotin Treating Patients With Relapsed Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) temsirolimus combination brentuximab vedotin patient relapse refractory Hodgkin lymphoma . II . To assess safety brentuximab vedotin combination temsirolimus patient relapse refractory Hodgkin lymphoma . III . To assess toxicity profile regimen patient . SECONDARY OBJECTIVES : I . Determine overall response rate ( ORR ) combination brentuximab vedotin temsirolimus relapse refractory Hodgkin lymphoma . II . Evaluate role inflammatory marker , interleukin ( IL ) -6 , IL-1 , tumor necrosis factor alpha ( TNF alpha ) , IL-10 , early predictor treatment response . OUTLINE : This dose-escalation study temsirolimus . Patients receive temsirolimus intravenously ( IV ) 30-60 minute day 1 8 day 1 , 8 , 15 brentuximab vedotin IV 30 minute day 1 . Treatment repeat every 21 day 16 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Patients must histologically confirm cluster differentiation ( CD ) 30 positive relapse refractory Hodgkin lymphoma Measurable disease , define least one lesion &gt; 1.5 cm , great transverse diameter Patients must fail autologous stem cell transplant least 2 prior cytotoxic regimen Hodgkin lymphoma Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 ( Karnofsky &gt; = 60 % ) Life expectancy great 3 month Leukocytes &gt; = 3,000/mcL Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Total bilirubin within normal institutional limit &lt; 3 x upper limit normal patient Gilbert 's disease Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 Ã— institutional upper limit normal Creatinine = &lt; 1.5 x institutional upper limit normal OR creatinine clearance &gt; = 40 mL/min/1.73 m^2 patient creatinine level institutional normal Patients must evidence dyspnea rest , exercise intolerance , pulse oximetry &gt; 92 % breathing room air Patients must force expiratory volume 1 second ( FEV1 ) /forced vital capacity ( FVC ) &gt; 60 % pulmonary function test ( PFT ) , unless due large mediastinal mass Hodgkin 's lymphoma ( HL ) ; carbon monoxide diffusion capacity ( DLCO ) , FEV1 , FVC &gt; 50 % predict value Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant partner participate study , inform treat physician immediately ; men treat enrolled protocol must also agree use adequate contraception prior study , duration study participation , 4 month completion temsirolimus brentuximab vedotin administration Ability understand willingness sign write informed consent document Fasting serum cholesterol = &lt; 300 mg/dL OR = &lt; 7.75 mmol/L AND fast triglyceride = &lt; 2.5 x upper limit normal ( ULN ) ; NOTE : In case one threshold exceed , patient include initiation appropriate lipid lower medication Patients know human immunodeficiency virus ( HIV ) infection must CD4 count great 200 ; antiretroviral agent induce inhibit cytochrome P450 ( CYP ) 3A4 activity allow Patients eligible autologous stem cell transplant unless refuse receive autologous stem cell transplant Patients chemotherapy radiotherapy within 3 week registration recover adverse event due agent administer 3 week earlier ; Note : patient consider enrolled study protocol registration sign consent Patients receive brentuximab vedotin within 6 month enrol study Patients receive investigational agent Patients know cerebral meningeal involvement lymphoma exclude clinical trial History allergic reaction attribute compound similar chemical biologic composition temsirolimus brentuximab vedotin Patients receive medication substance inhibitor inducer CYP3A4 ineligible Uncontrolled intercurrent illness include , limited , ongoing active infection , uncontrolled diabetes , clinically significant pneumonitis , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant woman exclude study ; breastfeed discontinue mother treated temsirolimus brentuximab vedotin Previous primary progression grade 3 toxicity treatment brentuximab vedotin Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent , except corticosteroid daily dosage equivalent prednisone = &lt; 20 mg ; topical inhale corticosteroid allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>